Naslov
Catestatin serum levels in male patients with obstructive sleep apnea

Autori
Božić, Joško ; Borovac, Josip Anđelo ; Šupe Domić, Daniela ; Galić, Tea ; Đogaš, Zoran

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Special Issue: Abstracts of the 24th Congress of the European Sleep Research Society / Riemann, Dieter - Oxford : John Wiley & Sons, 2018, 395-395

Skup
24th Congress Of The European Sleep Research Society

Mjesto i datum
Basel, Švicarska, 25.09.2018. - 28.09.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
catestatin ; obstructive sleep apnea ; sympathetic overactivity ; sympathetic dysregulation

Sažetak
Objectives/Introduction: Catestatin is a neuroendocrine multifunctional peptide involved in regulation of arterial blood pressure and inhibition of catecholamine secretion and sympathetic activity. Concordantly, obstructive sleep apnea (OSA) is marked by autonomic, cardiometabolic and inflammatory dysregulation thus affecting multiple organ systems. The goal of the present study was to determine and compare catestatin serum levels between male OSA patients and healthy control subjects. Additionally, we aimed to investigate the potential discriminatory role of catestatin as a biomarker of positive OSA status. Methods: In this cross‐sectional study, 40 OSA patients and 40 age/sex/BMI‐matched control subjects were consecutively enrolled. Each subject underwent anthropometric measuring and peripheral blood sampling while OSA patients also underwent a full‐night polysomnography. Catestatin serum levels were determined by the enzyme‐linked immunosorbent assay (ELISA). The area under the curve (AUC) was determined by the receiver operating characteristics (ROC) analysis. Results: A total of 80 male subjects were enrolled in the study, with no significant differences between OSA and control group in respect to age (50.6 ± 10.4 vs. 50.9 ± 7.7 years, p = 0.903) and BMI (30.4 ± 2.9 vs. 29.8 ± 2.9 kg/m2, p = 0.356). Both groups did not differ in any anthropometric measures, except that OSA group had significantly higher neck circumference compared to control group (42.0 ± 3.6 vs. 38.9 ± 2.3 cm, p < 0.001). Regarding the baseline polysomnographic parameters of OSA population, mean apneahypopnea index (AHI) was 42.8 ± 17.4 events/hr with mean oxygen desaturation index (ODI) of 38.9 ± 18.4 events/hr. Catestatin serum levels were significantly higher in OSA group compared to controls (3.1 ± 1.5 vs. 1.3 ± 0.8 ng/mL, p < 0.001). The obtained AUC value for serum catestatin as a predictor for positive OSA status was 0.88 (±SE 0.037, 95% CI 0.81–0.96, p < 0.001) with a cut‐off value of 2.0 ng/mL providing 80% sensitivity and 80% specificity in detection of OSA status. Conclusions: Serum catestatin levels were significantly higher in OSA patients than matched control subjects and were a robust indicative of OSA status. However, further studies are required to elucidate the mechanistic role of catestatin in complex pathophysiology of OSA and its suppressive role in sympathetic system overactivity.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA